Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337973 | 0.92 | TMEM97 (0.46) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL3340495 | 0.89 | TMEM97 (0.49) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL16210658 | 0.87 | TMEM97 (0.52) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL16379829 | 0.84 | DHFR (0.50) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL16220574 | 0.84 | DHFR (0.50) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL3336731 | 0.82 | TMEM97 (0.47) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL16210567 | 0.82 | DHFR (0.48) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL30902147 | 0.80 | PTGDR2 (0.51) | TMEM97SIGMAR1DHFRPTGDR2 | |
| SCHEMBL30421267 | 0.79 | TMEM97 (0.46) | TMEM97SIGMAR1DHFRKDRPTGDR2 | |
| SCHEMBL1831787 | 0.78 | MEN1 (0.50) | TMEM97SIGMAR1DHFRKDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | TMEM97 988/4885SIGMAR1 1764/4885DHFR 1547/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | TMEM97 985/4885SIGMAR1 1357/4885DHFR 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.